The Outcomes of COVID-19 Patients with Spontaneous Intracerebral Hemorrhage Comorbidity and the Efficacy of Enoxaparin in Decreasing the Mortality Rate in Them: Single Egyptian Center Report

Mohamed Shaban 1,*, Marwa O. Elgendy 2,3,*, Alzhraa M. Fahmy 4,*, Doaa Mahmoud Khalil 5, Ahmed O. El-Gendy 6, Tamer M. Mahmoud 7 and Mohamed E. A. Abdelrahim 8

Abstract: Patients with neurological comorbidities are more likely to develop severe COVID-19. We aimed to detect the outcomes of COVID-19 patients with spontaneous intracerebral hemorrhage comorbidity and the role of enoxaparin in decreasing the mortality rate in these cases, even though enoxaparin is a potential cause of intracerebral hemorrhage. The patients were checked on to detect surveillance outcomes, the relationship between mortality and patient characteristics, and the relationship between enoxaparin and study outcomes. Chest condition and GCS improved in 67.9% of participants. Hematoma course increased in 49.1%. Midline-shift, brain-edema, and COVID symptoms improved in 67.9%. There was a non-significant difference in mortality regarding age and gender. There was a significant difference in mortality regarding treatment with enoxaparin; 75% of the patients who did not receive enoxaparin died. 92.6% of the patients who showed decreases in hematoma course were administered enoxaparin. 76.9% of the patients who showed increases in hematoma course were administered enoxaparin. Most of the patients who were admitted to the neurosurgical unit with spontaneous intracerebral hemorrhage acquired the COVID-19 infection. Most of the cases included in this study did not progress to severe cases. The dying patients showed deterioration in both neurological and COVID-19 symptoms. The anticoagulant properties of enoxaparin given earlier before and throughout the infection can considerably reduce mortality in COVID-19 individuals with spontaneous intracerebral hemorrhage. It is recommended to use enoxaparin for cases with spontaneous intracerebral hemorrhage and COVID-19 regardless of hematoma size because the rate of improvement was greater than the mortality rate after using enoxaparin in this study.

Keywords: neurological disorders; enoxaparin; spontaneous intracerebral hemorrhage; COVID-19

1. Introduction

Coronavirus infection is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. It often appears as respiratory tract symptoms and fever [2–5]. To evaluate the patients with COVID-19 infection, the Dutch Radiological Society developed a score
system based on chest CT and patient data in March 2020; the COVID-19 Reporting and Data System (CO-RADS) included clinical findings and laboratory test results, as well as CT records. The level of suspicion ranged from very low to very high (CO-RADS categories 1–5), with category 0 indicating no infection and category 6 indicating RT-PCR-positive SARS-CoV-2 infection at the time of examination. [1]. In clinical settings, coronavirus may cause severe symptoms, particularly in elderly patients with many comorbidities [6]. The risk factors (comorbidities) for severe coronavirus symptoms include cerebrovascular disease, diabetes mellitus, cardiovascular disease, hypertension, and intracerebral hemorrhage (ICH) [7]. A growing number of studies on coronavirus have reported many neurological complications, such as Guillain–Barré syndrome [8], acute stroke, hyposmia, and encephalitis [9,10]. It has been demonstrated that approximately 30% of coronavirus patients develop neurological complications, which are frequently linked to a more severe infection, implying that coronavirus neurotropism is a possible mechanism of neurological damage [11,12]. ICH is indeed a very rare but well-documented COVID-19 complication [13]. Therefore, ICH can be regarded as a risk factor (comorbidity) and a complication of severe coronavirus infection. Many research studies looked at the ICH as a COVID-19 complication, but few published studies look at the ICH as a pre-existing comorbidity for severe coronavirus infection. Accordingly, we decided to conduct an observational study to detect the outcomes of COVID-19 patients with pre-existing spontaneous ICH (comorbidity). Primary ICH can happen in the presence or absence of known risk factors such as arterial hypertension (HTN) or anticoagulation therapy (such as enoxaparin) as a COVID-19 thrombo-prophylaxis [14–16]. A prior study found that moderate-to-severe coronavirus patients benefit from anticoagulant therapy, such as enoxaparin, in terms of lowering mortality in this disease [17–19]. Then, we decided to detect the role of enoxaparin in decreasing the mortality rate in COVID-19 patients with pre-existing spontaneous ICH, even though it is a potential cause for worsening ICH.

Therefore, the objective of this study was to detect the outcomes of COVID-19 patients with pre-existing spontaneous intracerebral hemorrhage (comorbidity) and to detect the role of enoxaparin in decreasing the mortality rate in these cases, although it is a potential cause for worsening intracerebral hemorrhage.

2. Materials and Methods

2.1. The Study Design

A cohort study was conducted from May 2021 to December 2021, including 102 patients who were admitted to the neurosurgical unit with spontaneous ICH. The study protocol was approved by the Research Ethical Committee of Beni-Suef University (REC-H-PhBSU-20010, date of approval: March 2021) and was carried out at Beni-Suef University Hospital following the Helsinki Declaration. The patient’s family provided written informed consent. Of the total patients, 53 patients were infected with SARS-CoV-2, and they were laboratory-confirmed as having SARS-CoV-2 infection using reverse transcription-polymerase chain reaction (RT-PCR). The patients were treated for COVID-19 according to the guidelines of the World Health Organization (WHO) and the Egyptian protocol.

Through repeated negative RT-PCR tests performed within 45 days of the initial positive test, SARS-CoV-2 clearance was determined in all surviving patients.

2.1.1. Inclusion Criteria

- Patients were more than 18-years-old.
- Patients were admitted to the hospital for spontaneous intracerebral hemorrhage and acquired COVID-19 infection during the period of their hospital admission.
- Positive cases of COVID-19 by RT-PCR test.

2.1.2. Exclusion Criteria

- Severe hepatic disease patients.
- Patients who were pregnant or lactating.
• Patients aged less than 18-years-old.

2.2. Sampling Techniques

The data collected from patients who had pre-existing spontaneous intracerebral hemorrhage comorbidities after confirmation of their infection with COVID-19 were analyzed.

2.3. Data Collection

From the patients, the following was collected:
1. The participants’ characteristics and disease characteristics of COVID-19 disease symptoms and computed tomography (CT) scan.
2. The neurological symptoms and CT brain findings on admission.
3. Management of the studied patients regarding their COVID-19 disease and neurosurgical management.
4. The outcomes of the patients who were studied.
5. The association between mortality and various patient characteristics.
6. The relation between enoxaparin and the outcome of the study.

Neurological parameters were collected for follow-up and monitoring of the patients to detect the link between patients’ neurological comorbidities and disease severity (recovery time) and clinical prognosis.

2.4. Statistical Analysis

The data were analyzed using IBM SPSS advanced statistics version 22 (SPSS Inc., Chicago, IL, USA), and the numerical data are expressed as mean and standard deviation or median and range, as appropriate. The qualitative data are expressed as frequency and percentage. The comparison between subgroups was performed using an independent t-test regarding scale variables, while the comparison regarding categorical variables was done using chi-squared or Fisher exact tests. A p-value < 0.05 was considered statistically significant.

3. Results

3.1. Participants’ Characteristics and COVID-19 Disease Characteristics (Symptoms and CT)

A total of 53 patients (30 males) completed the study. Their age (mean ± SD) was (59.1 ± 14.2). Regarding oxygen therapy, 60.4% of the patients required ordinary oxygen therapy, 18.9% required high-flow nasal oxygen therapy, and 20.8% required mechanical ventilation.

The characteristics of the studied patients and the disease characteristics of COVID-19 (symptoms and CT) are shown in Table 1.

Table 1. Characteristics of the studied patients and disease characteristics of COVID-19 (symptoms and CT).

| Characteristics                                      | Values No. = 53 (%) |
|------------------------------------------------------|---------------------|
| Age (mean ± SD)                                      | 59.1 ± 14.2         |
| Sex                                                   |                     |
| Females                                              | 23 (43.4%)          |
| Males                                                | 30 (56.6%)          |
| Fever                                                | 15 (28.3%)          |
| Dyspnea                                              | 13 (24.5%)          |
| Diarrhea                                             | 14 (26.4%)          |
| nausea and vomiting need to oxygen                   | 14 (26.4%)          |
| Ordinary oxygen therapy                              | 32 (60.4%)          |
| high flow nasal                                      | 10 (18.9%)          |
| Mechanical Ventilation                               | 11 (20.8%)          |
| CT chest                                              |                     |
| CORAD 3                                               | 27 (50.9%)          |
| CORAD 4                                               | 16 (30.2%)          |
| CORAD 5                                               | 10 (18.9%)          |
3.2. The Neurological Symptoms and CT Brain Findings on Admission

The mean Glasgow Coma Scale (GCS) for the patients was 11.5. Of all the patients (regarding the conscious patients), 1.9% suffered from diminished vision, 5.7% suffered from headache, 35.8% had left-side weakness and 26.4% had a right-side weakness. Regarding the CT brain findings, 28.3% of the patients had midline shift and brain edema, 5.7% had bilateral basal ganglia hematoma, 7.5% had left basal ganglia hematoma, and 5.7% had right basal ganglia hematoma. 9.4% had bilateral thalamic hematoma, 5.7% had left thalamic hematoma, and 26.4% had a right thalamic hematoma. 3.8% had bilateral temporo-parietal hematoma, 9.4% had left temporo-parietal hematoma, and 1.9% had right temporo-parietal hematoma. 1.9% had a bilateral frontal hematoma and 1.9% had a right frontal hematoma. 24.6% had intraventricular hemorrhage (IVH), 3.8% had a pontine hemorrhage, and 5.7% had hydrocephalus. The mean hematoma size ± SD was 14.9 ± 11.9. The hematoma course on admission was stationary in 28.3% of the participants, regressive in 22.6%, and progressive in 49.1% of them. The neurological symptoms and CT brain findings are shown in Table 2.

Table 2. Neurological symptoms and CT brain findings on admission.

| Items                                      | Values No. = 53 (%) |
|--------------------------------------------|---------------------|
| GCS (mean ± SD)                            | 11.5 ± 3.5          |
| median(IQR)                                | 13 (8)              |
| Headache                                   | 3 (5.7%)            |
| diminished vision                          | 1 (1.9%)            |
| Weakness                                   |                     |
| left side                                  | 19 (35.8%)          |
| right side                                 | 14 (26.4%)          |
| CT findings                                |                     |
| -basal ganglia hematoma                    |                     |
|   bilateral                                | 3 (5.7%)            |
|   left                                     | 4 (7.5%)            |
|   right                                    | 3 (5.7%)            |
| -thalamic hematoma                         |                     |
|   bilateral                                | 5 (9.4%)            |
|   left                                     | 3 (5.7%)            |
|   right                                    | 14 (26.4%)          |
| -temporo-parietal hematoma                 |                     |
|   bilateral                                | 2 (3.8%)            |
|   left                                     | 5 (9.4%)            |
|   right                                    | 1 (1.9%)            |
| -frontal hematoma                          |                     |
|   bilateral                                | 1 (1.9%)            |
|   right                                    | 1 (1.9%)            |
| -midline shift and brain edema             |                     |
|   IV hemorrhage                            | 15 (28.3%)          |
|   pontine hemorrhage                       | 13 (24.6%)          |
|   Hydrocephalus                            | 2 (3.8%)            |
|   hematoma size (mean ± SD)                | 14.9 ± 11.9         |
|   median(IQR)                              | 9 (14)              |
| Hematoma course on admission               |                     |
|   stationary                               | 15 (28.3%)          |
|   regressive                               | 12 (22.6%)          |
|   progressive                              | 26 (49.1%)          |
3.3. Management of the Studied Patients regarding Their COVID-19 Disease and Neurosurgical Management

Of all the study patients, 32.1% received a prophylactic dose of enoxaparin on day 3, 52.8% received a prophylactic dose on day 3, followed by a therapeutic dose on day 7, and 15.1% did not receive enoxaparin. Regarding the neurosurgical management, 9.4% of the patients were evacuated, and 5.7% underwent ventriculo-subglia drain (VSD) surgery. Management of the studied patients regarding their COVID-19 disease and neurosurgical management is shown in Table 3.

Table 3. Management of the studied patients regarding their COVID-19 disease and neurosurgical management.

| Items                             | Values No. = 53 (%) |
|-----------------------------------|---------------------|
| Enoxaparin                        |                     |
| No                                |                     |
| Prophylactic dose on day 3        | 8 (15.1%)           |
| Prophylactic dose on day 3 then therapeutic dose on day 7  | 17 (32.1%)         |
| surgical management               |                     |
| Evacuation                        | 5 (9.4%)            |
| VSD (ventriculo-subglia drain)    | 3 (5.7%)            |

3.4. The Outcomes of the Studied Patients

The condition of the chest and GCS had improved in 67.9% of the participants by the end of the study. The hematoma course increased in 49.1% of the patients. The midline shift, brain edema, and COVID symptoms improved in 67.9% of the participants. The outcomes of the patients who were studied are shown in Table 4.

Table 4. The outcomes of the studied patients.

| Items                                | Values No. = 53 (%) |
|--------------------------------------|---------------------|
| Chest Condition                      |                     |
| Improved                             | 36 (67.9%)          |
| Not improved                         | 17 (32.1%)          |
| Headache                             |                     |
| Improved                             | 3 (100%)            |
| Not improved                         | 0 0                 |
| GCS                                  |                     |
| Improved                             | 36 (67.9%)          |
| Not improved                         | 17 (32.1%)          |
| Weakness                             |                     |
| Improved                             | 0 0                 |
| Not improved                         | 33 (100%)           |
| Hematoma course                      |                     |
| decreased                            | 27 (50.9%)          |
| increased                            | 26 (49.1%)          |
| Medline shift and brain edema        |                     |
| Improved                             | 36 (67.9%)          |
| Not improved                         | 17 (32.1%)          |
| COVID-19 symptoms                    |                     |
| Improved                             | 36 (67.9%)          |
| Not improved                         | 17 (32.1%)          |
3.5. The Relation between Mortality and Different Patients’ Characteristics

There was no significant difference in mortality between patients depending on gender and age. However, there was a significant difference in mortality among patients depending on chest condition, COVID-19 symptoms, GCS, midline shift, and brain edema ($p$-value < 0.001). There was a significant difference in mortality among patients with temporo-parietal hematoma ($p$-value = 0.047). There was a significant difference in mortality among patients depending on hematoma size ($p$-value < 0.001). The hematoma sizes (mean ± SD) were $(4.612 ± 5.67)$ and $(13.00 ± 3.202)$ for the living and dead patients, respectively. There was a significant difference in the mortality among patients depending on the treatment with enoxaparin, where 75% of the patients who did not receive enoxaparin died, while in patients who were administered enoxaparin, it was 24.4% ($p$-value = 0.026). The ICU stay duration (mean ± SD) was $(12.28 ± 7.7)$ and $(7.29 ± 5.193)$ for the living and dead patients, respectively ($p$-value = 0.019). The relationship between mortality and different patients’ characteristics is shown in Table 5.

Table 5. Relations between mortality and different patients’ characteristics.

| Characteristics                        | Alive (No. = 36) | Died (No. = 17) | $p$-Value |
|----------------------------------------|------------------|-----------------|-----------|
| Age (mean ± SD)                        | 59.14 ± 13.508   | 59.00 ± 16.109  | 0.974     |
| Sex                                    |                  |                 |           |
| Females                                | 17 (73.9%)       | 6 (26.1%)       | 0.413     |
| Males                                  | 19 (63.3%)       | 11 (36.7%)      |           |
| need to oxygen                         |                  |                 |           |
| Ordinary oxygen therapy                | 26 (81.3%)       | 6 (18.8%)       |           |
| high flow nasal mechanical ventilation | 8 (80.0%)        | 2 (20.0%)       |           |
|                                        | 2 (18.2%)        | 9 (81.8%)       |           |
| CT chest                               |                  |                 |           |
| CORAD 3                                | 20 (74.1%)       | 7 (25.9%)       |           |
| CORAD 4                                | 15 (93.8%)       | 1 (6.3%)        |           |
| CORAD 5                                | 1 (10.0%)        | 9 (90.0%)       |           |
| GCS (mean ± SD)                        | 13.3 ± 1.7       | 7.53 ± 4.064    | <0.001 *  |
| midline shift and brain edema          |                  |                 |           |
| No                                     | 32 (84.2%)       | 6 (15.8%)       | <0.001 *  |
| yes                                    | 4 (26.7%)        | 11 (73.3%)      |           |
| basal ganglia                          |                  |                 |           |
| hematoma                               |                  |                 |           |
| No                                     | 29 (67.4%)       | 14 (32.6%)      |           |
| bilateral                              | 2 (66.7%)        | 1 (33.3%)       | FET       |
| left                                   | 4 (100.0%)       | 0 (0.0%)        | 0.308     |
| right                                  | 1 (33.3%)        | 2 (66.7%)       |           |
| thalamic hematoma                      |                  |                 |           |
| No                                     | 19 (61.3%)       | 12 (38.7%)      |           |
| bilateral                              | 3 (60.0%)        | 2 (40.0%)       | FET       |
| left                                   | 3 (100.0%)       | 0 (0.0%)        | 0.520     |
| right                                  | 11 (78.6%)       | 3 (21.4%)       |           |
| temporo-parietal                       |                  |                 |           |
| hematoma                               |                  |                 |           |
| No                                     | 33 (73.3%)       | 12 (26.7%)      |           |
| bilateral                              | 1 (50.0%)        | 1 (50.0%)       | FET       |
| left                                   | 1 (20.0%)        | 4 (80.0%)       | 0.047 *   |
| right                                  | 1 (100.0%)       | 0 (0.0%)        |           |
| Characteristics                          | Alive (No. = 36) | Died (No. = 17) | p-Value |
|-----------------------------------------|------------------|-----------------|---------|
| frontal hematoma                        |                  |                 |         |
| No                                      | 34 (66.7%)       | 17 (33.3%)      |         |
| bilateral                               | 1 (100.0%)       | 0 (0.0%)        | FET 0.475 |
| right                                   | 1 (100.0%)       | 0 (0.0%)        |         |
| IV hemorrhage                           |                  |                 |         |
| No                                      | 26 (65%)         | 14 (35%)        | FET 0.471 |
| Yes                                     | 10 (76.9%)       | 3 (23.1%)       |         |
| pontine hemorrhage                      |                  |                 |         |
| No                                      | 34 (66.7%)       | 17 (33.3%)      | 0.457   |
| Yes                                     | 2 (100.0%)       | 0 (0.0%)        | FET     |
| Hydrocephalus                           |                  |                 |         |
| No                                      | 33 (66.0%)       | 17 (34.0%)      | 0.305   |
| Yes                                     | 3 (100.0%)       | 0 (0.0%)        |         |
| hematoma size(mean ± SD)                | 4.61 ± 2.567     | 13.00 ± 3.202   | <0.001 * |
| Hematoma course on admission            |                  |                 |         |
| stationary                              | 15 (100%)        | 0 (0%)          | <0.001 * |
| regressive                              | 12 (100%)        | 0 (0%)          | <0.001 * |
| progressive                             | 9 (34.6%)        | 17 (65.4%)      | 0.333   |
| Enoxaparin                              |                  |                 |         |
| No                                      | 2 (25.0%)        | 6 (75.0%)       | 0.026 * |
| Prophylactic dose on day3               | 13 (76.5%)       | 4 (23.5%)       |         |
| Prophylactic dose on day3 then therapeutic dose on day 7 | 21 (75.0%) | 7 (25.0%) |         |
| Chest Condition                         |                  |                 |         |
| Improved                                | 36 (100.0%)      | 0 (0.0%)        | <0.001 * |
| Not improved                            | 0 (0.0%)         | 17 (100.0%)     |         |
| Headache                                |                  |                 |         |
| Improved                                | 3 (100.0%)       | 0 (0.0%)        | <0.001 * |
| Not improved                            | 0 (0.0%)         | 0 (0.0%)        |         |
| GCS                                     |                  |                 |         |
| Improved                                | 36 (100.0%)      | 0 (0.0%)        | <0.001 * |
| Not improved                            | 0 (0.0%)         | 17 (100.0%)     |         |
| Weakness (no = 39)                      |                  |                 |         |
| Improved                                | 0 (0%)           | 0 (0%)          | <0.001 * |
| Not improved                            | 30 (91%)         | 3 (9%)          |         |
| Hematoma size                           |                  |                 |         |
| -Stable or decrease                     | 36 (100.0%)      | 0 (0.0%)        | <0.001 * |
| -Increase                               | 0 (0.0%)         | 17 (100.0%)     |         |
| Medline shift and brain edema           |                  |                 |         |
| Improved                                | 36 (100.0%)      | 0 (0.0%)        | <0.001 * |
| Not improved                            | 0 (0.0%)         | 17 (100.0%)     |         |
| COVID-19 symptoms                       |                  |                 |         |
| Improved                                | 36 (100.0%)      | 0 (0.0%)        | <0.001 * |
| Not improved                            | 0 (0.0%)         | 17 (100.0%)     |         |
| ICU stay (days)                         | 12.28 ± 7.700    | 7.29 ± 5.193    | 0.019   |

(*) means significance.
3.6. The Relationship between Enoxaparin and the Outcome of the Study

Of all the patients who were treated with enoxaparin, 94.4% showed significant improvement in their chest condition, the mean Glasgow Coma Scale (GCS), the midline shift, brain edema, and COVID-19 symptoms ($p$-value = 0.01). An amount of 55.6% of the patients who were administered enoxaparin showed decreases in hematoma course and 25% who did not receive enoxaparin. Enoxaparin was given to 94.4% of the patients who were still alive. The relationship between enoxaparin and the study outcome is shown in Table 6.

Table 6. Relations between enoxaparin and the outcome of the study (presentations, mortality, and ICU stay).

| Items                          | Not Administered Enoxaparin (No. = 8) | Administered Enoxaparin (No. = 45) | $p$-Value |
|-------------------------------|--------------------------------------|-----------------------------------|----------|
| Chest Condition               | Improved                             | 2 (5.6%)                          | 34 (94.4%) | 0.010 * |
|                               | Not improved                         | 6 (35.3%)                         | 11 (64.7%) |
| GCS                           | Improved                             | 2 (5.6%)                          | 34 (94.4%) | 0.010 * |
|                               | Not improved                         | 6 (35.3%)                         | 11 (64.7%) |
| Weakness                      | Improved                             | 0 (0%)                            | 0 (0%)    | 0.850   |
|                               | Not improved                         | 2 (6%)                            | 31 (94%)  |
| Hematoma course               | decreased                            | 2 (7.4%)                          | 25 (92.6%) | 0.010 * |
|                               | increased                            | 6 (23.1%)                         | 20 (76.9%) |
| Medline shift and brain edema | Improved                             | 2 (5.6%)                          | 34 (94.4%) | 0.010 * |
|                               | Not improved                         | 6 (35.3%)                         | 11 (64.7%) |
| COVID-19 symptoms             | Improved                             | 2 (5.6%)                          | 34 (94.4%) | 0.010 * |
|                               | Not improved                         | 6 (35.3%)                         | 11 (64.7%) |
| Mortality                     | Alive                                | 2 (5.6%)                          | 34 (94.4%) | 0.010 * |
|                               | Died                                 | 6 (35.3%)                         | 11 (64.7%) |
| ICU stay (days)               |                                      | 2.38 ± 744                        | 12.16 ± 6.974 | 0.019 * |

(*) means significance.

4. Discussion

The findings of this study imply that coronavirus may worsen neurological disorders and, subsequently, mortality in people who have a pre-existing spontaneous intracerebral hemorrhage. This was also reported in previous studies [7,20,21].

According to a recent retrospective study, inpatients in a neurological unit who were infected with COVID-19 had a worse prognosis, developed severe cases, and experienced poorer outcomes than those who were not infected [13].

This is the first Egyptian study that shows how COVID-19 can make neurological symptoms worse in people who already have pre-existing spontaneous intracerebral hemorrhage and how many people die from it.

In particular, approximately 32% of patients with pre-existing spontaneous intracerebral hemorrhage died after being infected with COVID-19 [22]. The patients who died had deteriorating neurological symptoms such as decreased GCS, increased hematoma course, med line shift, and brain edema, whereas COVID-19 infection causes the production of the central nervous system and systemic cytokines, prostaglandins, and monokines, which
cause patients with neurological disorders to experience an abrupt decrease in cognition and a worsening prognosis [7,23,24].

In this study, about 53% of the dead patients required mechanical ventilation, indicating poor clinical outcomes with an elevated occurrence of severe conditions which led to mortality [25]. Worsening chest conditions were reported in all the dead patients.

In this study, the majority of hematoma patients had severe coronavirus. This could be because these people have risk factors for severe coronaviruses, such as age, hypertension, and diabetes. These risk factors also increase the mortality rate [26].

The majority of the dead patients in this study showed an increased size of hemorrhage and edema with midline shift, which caused compression on the brain stem and development of the hematoma course into a state of being progressive, leading to death. This may explain why most of the patients with progressive hematoma courses in this study died. These findings were confirmed by the study of TM Tu et al. [27].

For patients with increased hematoma course (hematoma size greater than 30 ml), the patients underwent surgery to evacuate the hematoma if the GCS score was between 7 and 13 and if the chest condition did not develop into severe pneumonia [28]. Of all the participants in this study, five of them underwent evacuation of the hematoma.

Ventricular subglia drain (VSD) is surgery to drain excess CSF from the ventricles (hydrocephalus) into the subglia space to relieve tension regardless of the score of GCS and the chest condition [29]. Three patients in this study suffered from hydrocephalus and urgently underwent VSD surgery.

For patients with a GCS score of less than 7 or whose chest condition has developed to a severe degree, dehydration therapy is used to monitor the cerebral edema and decrease the intracranial hemorrhage until their condition allows them to undergo surgery [30]. Mannitol, albumin, and glycerin fructose are the most commonly used osmotherapy medicines. Mannitol is the most commonly used dehydrant [31]. In this study, furosemide and mannitol were used as dehydration therapies. This combination results in a greater decrease in the amount of water in the brain than mannitol alone did. Furosemide enhances the effect of mannitol on plasma osmolality, causing a greater decrease in brain water content [32].

Difficulties with spontaneous breathing and respiratory secretion cleaning may exacerbate pneumonia in patients with pre-existing spontaneous intracerebral hemorrhage [33,34]. About 32.1% of the patients used a prophylactic dose (20 mg/0.4 ml twice daily) of enoxaparin on day 3 of their symptoms, and 52.8% used a prophylactic dose on day 3, followed by a therapeutic dose (60 mg/0.4 ml twice daily) on day 7. Anticoagulant use should be continued for four weeks for antithrombotic prophylaxis [35,36]. Approximately two-thirds of the cases included in this study did not progress to severe, which is especially intriguing given their previously severe and debilitating clinical profile. This unexpected outcome could be explained by the fact that these patients were given an anticoagulant for the prevention of thromboembolism, which is a result of commonly suffering from immobility for an extended duration. In reality, because of their severe neurological dysfunction, the majority of the patients in our study were bedridden, and anticoagulant medication was initiated early in their hospitalization, before SARS-CoV-2 infection. Early anticoagulant therapy with enoxaparin has been proposed as a helpful treatment since it has been linked to lower mortality in severe instances [37,38]. The anticoagulant effects could be explained through two-pronged mechanisms: anticoagulant, which minimizes the disease’s damaging effect, and anti-inflammatory, which prevents severe SARS-CoV-2 infection manifestations. The discovery that anticoagulants decrease cytokine release in a variety of inflammatory situations lends support to our interpretation [39]. Several studies have also found that enoxaparin improves coagulation issues in coronavirus patients and has anti-inflammatory properties that lower IL-6 and increase lymphocyte percentage. Enoxaparin appears to be useful in the treatment of coronavirus [40,41]. Furthermore, the antiviral activity of several anticoagulants, such as enoxaparin, has been predicted and supported by recent research [40,41]. However, the risk of bleeding problems from anticoagulant drugs in people with SARS-CoV-2 should not be ignored [41].
In terms of oxygen therapy, 60.4% of the patients in this study received standard oxygen therapy, 18.9% required high-flow nasal oxygen therapy, and 20.8% required mechanical ventilation. This shows that these patients developed moderate-to-severe chest conditions and required ICU care. Regarding the CT chest findings, 50.9% of the patients in this study were CORAD 3, 30.2% were CORAD 4, and 18.9% were CORAD 5. This means that people who have a pre-existing spontaneous intracerebral hemorrhage can quickly go from mild to severe COVID-19, which can lead to death.

In this study, there was no statistically significant difference in mortality among patients based on gender or age. However, there was a statistically significant difference in mortality among patients based on the comorbid pre-existing spontaneous intracerebral hemorrhage such as GCS, midline shift, brain edema, and hematoma course.

The hematoma sizes (mean ± SD) were (4.612 ± 2.567) and (13.00 ± 3.202) for the living and dead patients, respectively. The rising mortality rate could be explained by a hyperimmune response caused by cytokine storms, or by a direct viral invasion of human brain cells via transcribrial, hematogenous, and neural retrograde dissemination routes [42]. Furthermore, angiotensin-converting enzyme 2 (ACE2) receptors produced by capillary endothelial cells in the brain may be involved in SARS-CoV-2-induced neurological problems. Endothelial rupture in the brain causes irreparable brain injury, contributing to SARS-CoV-2 neurologic symptoms pathophysiology [42]. Moreover, higher D dimer and CRP levels caused by a state of high inflammation and activation of the coagulation cascade may result in cerebrovascular problems in coronavirus patients. As a result, the potential processes could include a combination of immunological, vascular, and neural variables. A neurologic manifestation of COVID-19 may occur in addition to preexisting intracerebral hemorrhage. A prior study found a link between COVID-19 and neurological illnesses, with more than 30% of hospitalized coronavirus patients developing neurological disorders [43], ranging from mild to life-threatening in severity. As a result, it needs to be included in any individual’s differential diagnosis presenting with increasing neurological symptoms, particularly within the current epidemic. As a result, individuals with severe coronavirus infection, as well as previous neurological diseases, should be treated with special caution because they are more likely to die [44].

There was also a statistically significant difference in mortality between patients based on their treatment with enoxaparin (p-value = 0.026), where 75% of the patients who did not receive enoxaparin died. A recent study confirmed this finding, reporting that enoxaparin reduces mortality in coronavirus patients with moderate to severe cases [17]. Most patients (92.6%) who showed a decrease in hematoma course were administered enoxaparin. On the other hand, 76.9% of the patients who showed an increase in hematoma course were administered enoxaparin. As a result, we recommend using enoxaparin for patients with spontaneous intracranial hemorrhage and COVID-19 regardless of hematoma course because the rate of improvement was greater than the mortality rate after using enoxaparin in this study.

The increase in hematoma course in the patients who were administered enoxaparin, which caused their deaths, may have been due to large hematoma size and deterioration in GCS, as well as chest condition, which was also reported in previous studies [45,46]. Regarding the chest condition, oxygen saturation decreased in the blood, which led to anorexia and deteriorated consciousness and GCS. In patients with preexisting spontaneous intracerebral hemorrhage and COVID-19 infection, a lower GCS can be considered a predictor of poor outcomes [47,48].

5. Conclusions

Our findings suggest that more than half of the patients who were admitted to the neurosurgical unit with spontaneous intracerebral hemorrhage acquired COVID-19 infection during their hospitalization period. Nearly two-thirds of the cases included in this study did not progress to severe cases. A third of the study patients died as a result of deteriorating neurological and COVID-19 symptoms such as decreased GCS, increased...
hematoma course, med line shift, brain edema, and chest condition. The antithrombotic efficacy of enoxaparin given earlier, both before and throughout the COVID-19 infection, can considerably reduce mortality in COVID-19 individuals with pre-existing spontaneous intracerebral hemorrhage. It is recommended to use enoxaparin for patients with preexisting spontaneous intracerebral hemorrhage and COVID-19 regardless of hematoma size because, in this study, the rate of improvement was greater than the mortality rate after using enoxaparin.

Author Contributions: Conceptualization, M.S.; methodology, formal analysis, investigation, resources, data curation, writing—original draft preparation, writing—review and editing, M.S., M.O.E., A.M.F., D.M.K., A.O.E.-G., T.M.M. and M.E.A.A.; visualization, M.S.; supervision, M.S.; project administration, M.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Research Ethical Committee of Beni-Suef University (REC-H-PhBSU-20010, date of approval: March 2021).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data is available upon request.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Elgendy, M.O.; Khalaf, A.M.; El-Gendy, O.; Abdelrahman, M.A.; El Gendy, S.O.; Hamied, A.M.A.; Essam, O.; Al Amir, K.; Yousry, E.M.; Abdelrahim, M.E. An Observational Study on the Management of COVID-19 Patients in Limited-Resource Hospitals. J. Clin. Nurs. Res. 2022, 6, 43–53. [CrossRef]
2. Klok, F.A.; Kruip, M.J.H.A.; van der Meer, N.J.M.; Arbous, M.S.; Gommers, D.A.M.P.; Kant, K.M.; Kaptein, F.H.J.; van Paassen, J.; Stals, M.A.M.; Huisman, M.V.; et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 2020, 191, 145–147. [CrossRef] [PubMed]
3. Bengter, M.; Williams, O.; Siddiqui, J.; Sztriha, L. Intracerebral haemorrhage and COVID-19: Clinical characteristics from a case series. Brain Behav. Immun. 2020, 88, 940–944. [CrossRef] [PubMed]
4. Elgendy, M.O.; Elmawla, M.N.A.; Hamied, A.M.A.; El Gendy, S.O.; Abdelrahim, M.E.A. COVID-19 patients and contacted person awareness about home quarantine instructions. Int. J. Clin. Pract. 2020, 75, e13810. [CrossRef] [PubMed]
5. Elgendy, M.O.; El-Gendy, A.O.; Abdelrahim, M.E. Public awareness in Egypt about COVID-19 spread in the early phase of the pandemic. Patient Educ. Couns. 2020, 103, 2598–2601. [CrossRef]
6. Panciani, P.P.; Saraceno, G.; Zanin, L.; Renisi, G.; Signorini, L.; Fontanella, M.M. Letter: COVID-19 Infection Affects Surgical Outcome of Chronic Subdural Hematoma. Neurosurgery 2020, 87, E167–E171. [CrossRef]
7. Kubota, T. and N. Kuroda, Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review. Clin. Neurol. Neurosurg. 2021, 200, 106349. [CrossRef]
8. Bigaut, K.; Mallaret, M.; Baloglu, S.; Nemoz, B.; Morand, P.; Baicry, F.; Godon, A.; Voulemiot, P.; Kremer, L.; Chanson, J.-B.; et al. Guillin-Barre syndrome related to SARS-CoV-2 infection. Neurol. Neuroimmunol. Neuroinflamm. 2020, 7, e785. [CrossRef]
9. Ellul, M.A.; Benjamin, L.; Singh, B.; Lant, S.; Michael, B.D.; Easton, A.; Kneen, R.; Defres, S.; Sejvar, J.; Solomon, T. Neurological associations of COVID-19. Lancet Neurol. 2020, 19, 767–783. [CrossRef]
10. Elgendy, M.; Tayel, S.; Abdelrahim, M.; Ali, A.; Meabed, M. Role of Piracetam in Treatment of Cerebral Palsy Disease. J. Behav. Health 2012, 1, 53–58. [CrossRef]
11. Josephson, S.A.; Kamel, H. Neurology and COVID-19. JAMA 2020, 324, 1139–1140. [CrossRef]
12. Elgendy, M.O.; El-Gendy, A.O.; Alzarea, A.I.; Mahmoud, S.; Alqahtani, S.S.; Fahmy, A.M.; El-Seedi, H.R.; Sayed, A.M.; Alatawi, A.D.; Abdelrahim, M.E.A.; et al. SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population. Vaccines 2022, 10, 18. [CrossRef]
13. Margos, N.P.; Meintanopoulos, A.S.; Filioglou, D.; Ellul, J. Intracerebral hemorrhage in COVID-19: A narrative review. J. Clin. Neurosci. 2021, 89, 271–278. [CrossRef]
14. Herman, C.; Mayer, K.; Sarwal, A. Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19. Neurology 2020, 95, 77–84. [CrossRef]
15. Sayed, A.M.; Khalaf, A.M.; Abdelrahim, M.E.A.; Elgendy, M.O. Repurposing of some anti-infective drugs for COVID-19 treatment: A surveillance study supported by an in silico investigation. Int. J. Clin. Pract. 2020, 75, e13877. [CrossRef]
16. Zawbaa, H.M.; Osama, H.; El-Gendy, A.; Saeed, H.; Harb, H.S.; Madney, Y.M.; Abdelrahman, M.; Mohsen, M.; Ali, A.M.A.; Nicola, M.; et al. Effect of mutation and vaccination on spread, severity, and mortality of COVID-19 disease. J. Med. Virol. 2021, 94, 197–204. [CrossRef]
17. Billett, H.H.; Reyes-Gil, M.; Szymanski, J.; Ikemura, K.; Stahl, L.R.; Lo, Y.; Rahman, S.; Gonzalez-Lugo, J.D.; Kushnir, M.; Barouqa, M.; et al. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. *Thromb. Haemost.* 2020, 120, 1691–1699. [CrossRef]

18. Elgendy, M.O.; Abdelrahim, M.E.A. Public awareness about coronavirus vaccine, vaccine acceptance, and hesitancy. *J. Med. Virol.* 2021, 93, 6535–6543. [CrossRef]

19. Elgendy, M.O.; Elgendy, A.O.; Osama, H.; El-Gendy, A.O.; Abdelrahim, M.E.A. Role of repeating quarantine instructions and healthy practices on COVID-19 patients and contacted persons to raise their awareness and adherence to quarantine instructions. *Int. J. Clin. Pract.* 2021, 75, e14694. [CrossRef]

20. Eid, R.A.; Elgendy, M.O.; El-Gendy, A.O.; Elgendy, S.O.; Belbahri, L.; Sayed, A.M.; Rateb, M.E. Efficacy of Ceftazidime and Cefepime in the Management of COVID-19 Patients: Single Center Report from Egypt. *Antibiotics* 2021, 10, 1278. [CrossRef]

21. Elgendy, M.O.; El-Gendy, A.O.; Mahmoud, S.; Mohammed, T.Y.; Abdelrahim, M.E.A.; Sayed, A.M. Side Effects and Efficacy of COVID-19 Vaccines among the Egyptian Population. *Vaccines* 2022, 10, 109. [CrossRef] [PubMed]

22. Battistoni, I.; Francioni, M.; Morici, N.; Rubboli, A.; Podda, G.M.; Pappalardo, A.; Abdelrahim, M.E.; Elgendy, M.O.; Khalaf, A.M.; Hamied, A.A.M.; et al. Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: A propensity-matched analysis of in-hospital outcomes. *J. Cardiovasc. Med.* 2021, 23, 264–271. [CrossRef] [PubMed]

23. Cunningham, C. Systemic inflammation and delirium: Important co-factors in the progression of dementia. *Biochem. Soc. Trans.* 2011, 39, 945–953. [CrossRef] [PubMed]

24. Xu, J.; Zhong, S.; Liu, J.; Li, L.; Li, Y.; Wu, X.; Li, Z.; Deng, P.; Zhang, J.; Zhong, N.; et al. Detection of Severe Acute Respiratory Syndrome Coronavirus in the Brain: Potential Role of the Chemokine Mig in Pathogenesis. *Clin. Infect. Dis.* 2005, 41, 1089–1096. [CrossRef] [PubMed]

25. Hazariwala, V.; Hadid, H.; Kirsch, D.; Big, C. Spontaneous pneumomediastinum, pneumopericardium, pneumothorax and subcutaneous emphysema in patients with COVID-19 pneumonia, a case report. *J. Cardiothorac. Surg.* 2020, 15, 301. [CrossRef] [PubMed]

26. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *Lancet* 2020, 395, 1054–1062. [CrossRef]

27. Tu, T.M.; Goh, C.; Tan, Y.K.; Leow, A.S.; Pang, Y.Z.; Chien, J.; Shafi, H.; Chan, B.P.; Hui, A.; Koh, J.; et al. Cerebral Venous Thrombosis in Patients with Coronavirus Disease 2019 Infection: A Case Series and Systematic Review. *J. Stroke Cerebrovasc. Dis.* 2020, 29, 105379. [CrossRef]

28. Balasa, A.; Ghiga, D.; Andone, R.-S.; Zahan, A.; Florian, I.; Chinezu, R. Effects of Surgery on the 30-Day Survival Rate in Spontaneous Supratentorial Intracerebral Hemorrhage. *Brain Sci.* 2020, 11, 5. [CrossRef]

29. Verrees, M.; Selman, W.R. Management of normal pressure hydrocephalus. *Am. Fam. Physician* 2004, 70, 1071–1078.

30. Wang, W.; Zhou, N.; Wang, C. Minimally Invasive Surgery for Patients with Hypertensive Intracerebral Hemorrhage with Large Hematoma Volume: A Retrospective Study. *World Neurosurg.* 2017, 105, 348–358. [CrossRef]

31. Zheng, H.; Chen, C.; Zhang, J.; Chunli, C. Mechanism and Therapy of Brain Edema after Intracerebral Hemorrhage. *Cerebrovasc. Dis.* 2016, 42, 155–169. [CrossRef]

32. Thenuwara, K.; Todd, M.M.; Brian, J.E. Effect of Mannitol and Furosemide on Plasma Osmolality and Brain Water. *Anesth. Analg.* 2002, 96, 416–421. [CrossRef]

33. Alhazzani, W.; Møller, M.H.; Arabi, Y.M.; Loeb, M.; Gong, M.N.; Fan, E.; Dzierska, A. Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with COVID-19. *Intensive Care Med.* 2020, 46, 854–887. [CrossRef]

34. Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; McGinn, T.; Davidson, K.W.; The Northwell COVID-19 Research Consortium. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area. *JAMA* 2020, 323, 2052–2059. [CrossRef]

35. Di Gennaro, F.; Marotta, C.; D’Avanzo, C.; Foschini, N.; Maffei, L.; de Gaetano, G.; Centonze, D.; Iezzi, E. SARS-CoV-2 transmission and outcome in neuro-rehabilitation patients hospitalized at a neurorehabilitation hospital in Italy. *Medittr. J. Hematol. Infect. Dis.* 2020, 12, e2020063. [CrossRef]

36. Moein, S.T.; Hasheiman, S.M.R.; Mansourfashar, B.; Khorraram-Tousi, A.; Tabarsi, P.; Doty, R.L. Smell dysfunction: A biomarker for COVID-19. *Int. Forum Allergy Rhinol.* 2020, 10, 944–950. [CrossRef]

37. Tang, N.; Li, D.; Wang, X.; Sun, Z. Los parámetros anormales de coagulación están asociados con un pronóstico deficiente en pacientes con neumonía por coronavirus novedosa. *J. Thromb. Haemost.* 2020, 18, 844–847. [CrossRef]

38. Zhang, Y.; Cao, W.; Xiao, M.; Li, Y.J.; Yang, Y.; Zhao, J.; Zhou, X.; Jiang, W.; Zhao, Y.Q.; Zhang, S.Y.; et al. Clinical and coagulation characteristics of 7 patients with critical COVID-19 pneumonia and acro-ischemia. *Zhonghua Xue Ye Xue Za Zhi* 2020, 41, E006.

39. Mousavi, S.; Moradi, M.; Khoshidahmad, T.; Motamedi, M. Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review. *Adv. Pharmacol. Sci.* 2015, 2015, 507151. [CrossRef] [PubMed]
42. Baig, A.M.; Khaleeq, A.; Ali, U.; Syeda, H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem. Neurosci. 2020, 11, 995–998. [CrossRef] [PubMed]

43. Munhoz, R.P.; Pedroso, J.L.; Nascimento, F.A.; Almeida, S.M.D.; Barsottini, O.G.P.; Cardoso, F.E.C.; Teive, H.A.G. Neurological complications in patients with SARS-CoV-2 infection: A systematic review. Arq. Neuro-Psiquiatr. 2020, 78, 290–300. [CrossRef] [PubMed]

44. Katal, S.; Balakrishnan, S.; Gholamrezanezhad, A. Neuroimaging and neurologic findings in COVID-19 and other coronavirus infections: A systematic review in 116 patients. J. Neuroradiol. 2021, 48, 43–50. [CrossRef]

45. Zhai, Z.; Li, C.; Chen, Y.; Gerotziafas, G.; Zhang, Z.; Wan, J.; Liu, P.; Elalamy, I.; Wang, C.; On behalf of the Prevention Treatment of VTE Associated with COVID-19 Infection Consensus Statement Group; et al. Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. Thromb. Haemost. 2020, 120, 937–948. [CrossRef]

46. Watson, V.L.; Louis, N.; Seminara, B.V.; Muizelaar, J.P.; Alberico, A. Proposal for the rapid reversal of coagulopathy in patients with nonoperative head injuries on anticoagulants and/or antiplatelet agents: A case study and literature review. Neurosurgery 2017, 81, 899–909. [CrossRef]

47. Kembuan, M.A.H.N.; Mawuntu, A.H.P.; Yohanna, Y.; Feliana, F.; Tumboimbela, M.J. Lower GCS is Related to Poor Outcome among Acute Stroke Patients with COVID-19 in A Tertiary Referral Hospital in Indonesia. Indones. Biomed. J. 2021, 13, 409–417. [CrossRef]

48. Elgendy, S.O.; Elgendy, M.O.; El-Gendy, A.O.; Hamied, A.M.A.; Al Amir, K.; Gad, R.A.; Fahmy, A.M. Health Care Workers’ Awareness about the Post-COVID Syndrome and Different Types of COVID-19 Vaccines in Egypt. NeuroQuantology 2022, 20, 3830–3839.